• Explore /
  • Poster
  • / A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, <i>PIK3CA</i> mutant or wild-type breast cancer.

A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.

Abstract Poster

Authors

Ingrid Mayer

Ingrid A. Mayer

Vanderbilt-Ingram Cancer Center, Nashville, TN

Ingrid A. Mayer , Christian F. Singer , Peter A. Fasching , Frankie Ann Holmes , Michael Gnant , Laura G Estevez , Mario Campone , Michael Hubalek , Antonio C. Wolff , Jose Alejandro Perez-Fidalgo , Eric P. Winer , Gena Atalla-Vidam , Charu Kanwal , Lars Blumenstein , Nathalie Fretault , Ivan Diaz-Padilla , Carlos L. Arteaga

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01923168

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS633)

DOI

10.1200/jco.2015.33.15_suppl.tps633

Abstract #

TPS633

Poster Bd #

118a

Abstract Disclosures

Similar Posters

First Author: Ingrid A. Mayer

First Author: Guillaume Canaud

First Author: Hope S. Rugo

First Author: Nadia Harbeck